Contents

Ackno	wledgement	9
Introdu	action	11
Part I:	Methodology and definitions	15
I.1	Methodology	15
1.2	Definitions	16
Part II:	Description of the situation	19
II.1	Introduction	19
II.2	Prevalence of drug use among prisoners	19
II.3	What do we know about drug use in prison: drugs, patterns and frequency of use, routes of administration?	27
II.4	Drug use and drug-related deaths after release from Prison	36
II.5 II.5.1 II.5.2 II.5.3	Infectious diseases in European Prisons HIV/AIDS Hepatitis B/C Tuberculosis	39 39 42 45
II.6 II.6.1 II.6.2 II.6.3	Specific target groups: women, migrants and young offenders Women Migrants Young offenders	45 45 50 50

Part II	I: Description of the responses	51
III.1	Introduction	51
III.1.1	Organisation and practice of health care and assistance	
III.1.2	provided to drug users in prisons The principle of 'equivalence' in international guidelines and	53
	recommendations	60
III.1.3	Medical services and examination	63
III.1.4	Training of doctors and staff	63
III.2	Prevention	65
III.2.1	Prevention of drug use	65
	Supply reduction	68
III.2.1.2 III.2.2	Demand reduction	71
	Prevention of sexual transmission Provision of condoms	72
		73
III.3 III.3.1	Abstinence oriented treatment Detoxification	76
III.3.1 III.3.2	Drug-free units and drug-free wings	78
III.3.3	Therapeutic Communities in prison	81 87
III.4	Substitution Treatment	
III.4.1	Key issues of methadone prescription	88
III.4.2	Standards and guidelines for methadone prescription	102
III.5	Harm-reduction measures	107
III.5.1	The transfer of harm reduction strategies into the	114
221012	prison setting	115
III.5.2	Blood screening and HIV testing	115 117
III.5.3	Training and seminars	117
III.5.4	Vaccination programmes	122
	Provision of disinfectants	123
III.5.6	Needle exchange programmes	127
	Community Links	136
	Pre-Release units and release	137
	Aftercare	139
	Working with families and maintaining family ties	141
111.0.4	Throughcare	142

	III.6.5	Therapeutic Communities for sentenced offender			
	111.0.5	outside prison	144		
	III.6.6	Counselling and the involvement community health structures	144		
Part IV: Evaluation of demand and harm reduction					
		interventions in prisons in the EU	147		
	IV.1	Introduction	147		
	IV.2	Evaluation criteria	148		
	IV.3	Results of evaluations	149		
	Conclu	isions	163		
	Appen	dices: European Guidelines and Recommendations	177		
	Al	Prison and Drugs 1998: European Recommendations (The European Network of Drug and HIV/AIDS Services in Prison/Carl von Ossietzky University of Oldenburg)	177		
	A2	Prison and Drugs 1998: Youth and Women – European Recommendations (The European Network of Drug and HIV/AIDS Services in Prison)	184		
	A3	Conclusions of 'The European Peer Support Project phase 3: Risk reduction activities in prison' (Trimbos Institute Utrecht/ The Netherlands; Carl von Ossietzky University Oldenburg/ Germany, January 1998)	189		
	A4	European Guidelines on HIV/AIDS and Hepatitis in Prison (Milan, May 1999, Launched by the European Network on HIV and Hepatitis Prevention in Prison)	192		
	A5	Recommendation No. R (93)6 Of The Committee Of Ministers To Member States Concerning Prison And Criminological Aspects Of The Control Of Transmissible Diseases Including AIDS And Related Health Problems In Prison	197		
	A6	Council Of Europe, Committee Of Ministers, Recommendation No. R (98) 71 Of The Committee Of Ministers To Member States Concerning The Ethical And Organisational Aspects Of Health Care In Prison	204		

References	217
List of experts involved	241
Useful websites	247